Question explored with the scientific record
Which vaccines are safe?
The short version: no vaccine is "safe" in the abstract. Safety is a property of the match between a specific person, a specific product, and the evidence that was actually run.
The question "which vaccines are safe" cannot be answered as a list. Safety is not a stamp a regulator gives. It is a question of whether the evidence for a specific vaccine in a specific population is strong enough to justify the risk. The burden of proof is on whoever asks you to accept the injection, and that burden has not been met equally for every vaccine.
For the COVID-19 mRNA vaccines, the evidence on all-cause mortality is deeply contradictory. A Norwegian cohort study of 4.6 million adults found that people with three or more doses had about 58% lower adjusted all-cause mortality than the unvaccinated [2]. But a UK analysis of ONS data found that the relative risk of death for vaccinated people started lower and then rose over time, crossing the unvaccinated line between September 2022 and January 2025 depending on age [3]. A US county-level study of over 3,000 counties found that higher vaccination uptake was associated with more excess mortality in 2022 and 2023, not less [5]. And a re-analysis of Australian data concluded that the claim that vaccination reduced all-cause mortality by 51% in older adults is mathematically implausible, because it would require an excess death rate of 121% in the unvaccinated, which has never been seen in any OECD country [1]. These studies cannot all be true. The evidence base is not settled. It is a mess.
For influenza vaccination in older adults and people with diabetes, the evidence is more consistent but still observational. A meta-analysis of six studies in people with diabetes found that flu vaccination was associated with about 46% lower all-cause mortality [12]. A Dutch cohort of 223,580 adults found a 10% reduction [6]. But these are observational studies, not randomized trials. The healthy vaccinee effect, where healthier people are more likely to get vaccinated, can easily produce these numbers. The studies try to adjust for it, but adjustment is never perfect. The real effect is probably smaller than the headline number.
For the childhood vaccines, the evidence is older and thinner than most people realize. The 1982 review by Fenichel cataloged neurological complications after routine childhood immunizations: encephalopathy after DPT at about 1 in 110,000 doses, paralytic polio from the live oral polio vaccine at about 1 in 3 million doses, and encephalopathy after measles vaccine at about 1.16 per million doses [43]. Rotavirus vaccines carry a known risk of intussusception, with a relative incidence of about 7 to 10 in the first week after the first dose [44]. These are real risks, and they are not zero.
| Vaccine / Population | What the evidence shows | Key limitation |
|---|---|---|
| COVID-19 mRNA (all ages) | Contradictory: some studies show lower all-cause mortality, others show higher | No clean vaccinated vs unvaccinated RCT; healthy vaccinee bias; ecological studies conflict |
| Influenza (older adults, diabetics) | Observational studies show 10-46% lower all-cause mortality | Healthy vaccinee effect; no placebo-controlled RCTs in modern era |
| DPT (infants) | Encephalopathy risk ~1 in 110,000 doses | Estimates from 1980s passive surveillance; underreporting likely |
| Oral polio (infants) | Vaccine-associated paralytic polio ~1 in 3 million doses | Risk from live virus; eliminated in US with switch to inactivated polio vaccine |
| Rotavirus (infants) | Intussusception risk ~7-10x in first week after dose 1 | Benefit (preventing hospitalizations) likely outweighs risk, but risk is real |
My call: no vaccine is universally safe. The evidence for influenza vaccine in older adults and people with diabetes is the most consistent, but it is observational and the real benefit is probably modest. The evidence for COVID-19 mRNA vaccines is contradictory and unsettled. The childhood vaccines have documented risks that are small but real, and the long-term safety studies that would settle the question were never run.
Confidence: low for any blanket statement about vaccine safety. The evidence is too thin, too conflicted, and too dependent on who funded the study and who was left out of the comparison group.
Sources used 8
-
The Claim That COVID-19 Vaccination Protected Australians from All-Cause Mortality Is Not Plausible
Liu et al.'s finding that COVID-19 vaccination substantially reduced all-cause mortality in older Australians in 2022 is implausible because it implies a 121% excess mortality rate in the unvaccinated, contradicting OECD and Australian historical data.
DOI: 10.71189/jim/2026/v02n03a11 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
Neurological complications of immunization
A comprehensive 1982 review by Fenichel et al. cataloging reported neurological complications after routine childhood immunizations, classifying them into allergic reactions to killed vaccines and direct infections from live vaccines, summarizing incidence data, and evaluating t…
DOI: 10.1002/ana.410120202 -
Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program
This study evaluates the risk of intussusception associated with rotavirus vaccines RV1 and RV5 in Australia, finding a significant increase in risk shortly after vaccination but concluding that the overall benefits of vaccination outweigh the risks.
DOI: 10.1093/cid/cit520